At a glance
$70k
Retained + incremental revenue
$-1187187 vs Q2
Target $950k–1.05M
86.5%
Response time SLA
Target 80–85%
$56k
Retained revenue
$-937723 vs Q2
$14k
Sales gross revenue
Target $300–350k
3.1%
Lead to close
Target 1.6–1.75%
76.5%
CV Meds spent %
Target 65%
54.4%
First rebill
Target 75%
32.4%
Second rebill
Target 50%
90.3%
Shipping SLA %
Target 75%
15.5%
Cohort refund rate
Target ≤15%
4.46
Blended reputation
Target 4.5–4.6 · 192 reviews
$8.77
Total cost per contact
COGS + S&M ÷ contacts QTD
$9.00
Revenue per contact
Q3 QTD revenue ÷ total contacts Q3 QTD
$184k
Revenue per FH FTE
Run-rate (QTD rev ÷ days × 90) ÷ 7 FTEs · Target $172k/qtr
Detail
AreaMetricQ3 QTDQ2 Final
SalesGross revenue$14k$264k
SalesLead to close3.1%1.6%
RetentionRetained revenue$56k$994k
RetentionFirst rebill54.4%41.3%
PartnershipsCV Meds spent %76.5%76.3%
PartnershipsAlto SLA90.3%71.3%
Customer serviceCohort refund15.5%25.6%
Customer serviceCohort voided20.5%14.1%
Customer serviceResponse SLA86.5%85.6%
Customer serviceBlended reputation4.464.37
Initiative highlights v2
The team is off to a fast Q3 start. Sales is deploying a new checkout link generator by 7/8 — eliminating the manual Google Sheet dependency — while Phase 2 of the aged leads process (7-day window) goes live next week. Retention is expanding cross-training to all Tier 1 CCR agents with the full retention methodology. On partnerships, the Amazon Pharmacy Finance meeting is complete and FH moves to contract negotiations, with Functional Requirements scoped for the 7/15 Product meeting.
Heroes
$14k
Gross revenue QTD
Target $300–350k
3.1%
Lead to close
Target 1.6–1.75%
410.7%
Coverage rate
Target 100%
1.8%
Contact rate
Target 6–8%
$3.77
S&M cost per contact
S&M spend ÷ contacts QTD
Initiative updates
Checkout Link Generator Rolling Out 7/8
New checkout link generator deploys to the full team by Wednesday 7/8. This unblocks live handling of automatically assigned leads without the need for a manual Google Sheet download.
Rae Sykes · Jul 7
Aged Leads Phase 1 Live, Phase 2 Next Week
Phase 1 of the aged leads process (leads ≤7 days) is now live. Phase 2 rollout is on track for next week.
Josh Wagner · Jul 7
Workflow Optimization: Meds & Plans Integration
Integrating medication and plan offerings into the current sales flow to improve conversion and coverage.
Josh Wagner · Jul 7
Zendesk Sales Tracking Enhancement
Collaborating with Operations to enhance sales tracking capabilities in Zendesk for better pipeline visibility.
Josh Wagner · Jul 7
Detail metrics
MetricQ3 QTDQ2Target
Gross revenue$14k$264k$300–350k
Lead to close3.1%1.6%1.6–1.75%
Coverage rate410.7%121.1%100%
Conversion rate43.0%26.0%27–29%
Contact rate1.8%5.0%6–8%
AOV$327$261
Monthly revenue (2026 YTD)
Gross Revenue — monthly waterfall ($k)  * Jul partial (Q3 QTD)
Weekly trends (YTD)
Gross Revenue ($k)
Lead to Close (%)
Contact Rate (%)
Heroes
$56k
Retained revenue QTD
$-937723 vs Q2
54.4%
First rebill retention
Target 75%
32.4%
Second rebill
Target 50%
3.4%
Save %
Saved ÷ Cancel-reason tickets
$3.77
S&M cost per contact
S&M spend ÷ contacts QTD
Initiative updates
Tier 1 CCR Cross-Training on Retention
All Tier 1 agents will be cross-trained on the specialized retention methodology, expanding the team's toolbox to improve retention rates.
Rae Sykes · Jul 7
Detail metrics
MetricQ3 QTDQ2Target
Retained revenue$56k$994k$650–700k
Customers saved11523
Avg revenue per save$5k$2k
Save %3.4%7.5%Evolving
↳ Cancel-reason tickets QTD3257,010
First rebill retention54.4%41.3%55%
Second rebill retention32.4%20.3%50%
Save rate trend (weekly, YTD)
Weekly save rate trend will appear here once the retained revenue CSV (WBR - Retained Revenue) has been processed with the updated parse script.
Recurring revenue waterfall — by save cohort
Each row is a cohort of customers saved in that month. Each column is a billing month. Values show estimated revenue collected in that period, distributed proportionally across each billing date. Blue columns = Q2 2026.
Save Cohort # Oct '24 Nov '24 Dec '24 Jan '25 Feb '25 Mar '25 Apr '25 May '25 Jun '25 Jul '25 Aug '25 Sep '25 Oct '25 Nov '25 Dec '25 Jan '26 Feb '26 Mar '26 Apr '26 May '26 Jun '26 Jul '26
Oct '24$69k$75k$57k$49k$44k$34k$31k$28k$27k$25k$21k$18k$17k$14k$16k$12k$10k$9k$8k$9k$8k$1k
Nov '24$132k$112k$94k$78k$71k$54k$53k$44k$39k$34k$34k$28k$25k$21k$20k$16k$15k$13k$12k$10k$4k
Dec '24$87k$84k$64k$52k$42k$31k$27k$23k$22k$20k$18k$16k$16k$13k$9k$8k$8k$7k$6k$1k
Jan '25$104k$94k$74k$58k$46k$42k$34k$32k$28k$24k$23k$20k$22k$16k$15k$14k$12k$11k$4k
Feb '25$80k$85k$72k$59k$47k$39k$34k$29k$27k$25k$21k$19k$16k$14k$11k$9k$9k$1k
Mar '25$86k$96k$82k$66k$57k$49k$44k$38k$33k$29k$27k$22k$23k$17k$15k$16k$2k
Apr '25$81k$84k$67k$54k$48k$37k$29k$25k$24k$19k$16k$15k$13k$10k$8k$1k
May '25$68k$71k$62k$46k$37k$34k$28k$23k$22k$19k$17k$13k$10k$8k$2k
Jun '25$55k$74k$60k$48k$38k$33k$25k$20k$18k$15k$13k$13k$10k$3k
Jul '25$100k$130k$100k$86k$70k$55k$44k$35k$31k$28k$23k$21k$5k
Aug '25$111k$151k$119k$93k$74k$50k$40k$37k$29k$25k$23k$4k
Sep '25$91k$102k$83k$67k$52k$38k$28k$27k$25k$21k$3k
Oct '25$59k$64k$60k$43k$37k$29k$26k$20k$17k$3k
Nov '25$37k$50k$48k$34k$30k$28k$21k$17k$3k
Dec '25$24k$28k$24k$20k$17k$14k$15k$2k
Jan '26$22k$31k$28k$24k$23k$19k$4k
Feb '26$22k$40k$36k$28k$21k$6k
Mar '26$19k$29k$22k$18k$2k
Apr '26$21k$22k$18k$3k
May '26$7k$13k$3k
Jun '26$5k$2k
Jul '26
Total $69k$207k$256k$331k$360k$401k$435k$450k$446k$506k$587k$637k$621k$571k$525k$461k$405k$391k$374k$326k$293k$56k
Low revenue High revenue Before save date
Heroes
76.5%
CV Meds spent %
Target 65%
90.3%
Shipping SLA %
Target 75%
53.7%
Meds Shipped %
Target 95%
N/A
Meds Delivered %
Target 90%
Initiative updates
Amazon Pharmacy Contract Negotiations Advancing
AMZ Pharmacy Finance meeting completed. FH to provide additional documentation to initiate contract negotiations; Functional Requirements will be scoped in the Product meeting on 7/15.
Emily McCurdy · Jul 7
Weekly trends
CV Meds spent % (weekly, CareValidate)
First rebill % by MSO (weekly, mature cohorts)
Second rebill % by MSO (weekly, mature cohorts)
Alto pharmacy shipped % (by cohort week, ≤5 days)
Alto pharmacy delivered % (by cohort week, ≤7 days)
Detail metrics
MSO / AreaMetricQ3 QTDQ2Target
CAREVALIDATE
CareValidate Meds spent76.5%76.3%65–70%
Account creation87.8%87.2%95%+
First rebill56.5%N/A55%
Cohort refund12.8%11.4%≤15%
Cohort voided20.9%20.5%≤16%
BBB complaints01
OPENLOOP
OpenLoop Meds spent42.6%42.4%65–70%
Account creation84.0%83.9%95%+
First rebill59.8%54.6%55%
Cohort refund22.4%23.0%≤15%
Cohort voided13.4%15.1%≤16%
BBB complaints014
STEADYMD
SteadyMD First rebill48.6%40.0%55%
Cohort refund18.2%≤15%
Cohort voided22.1%≤16%
BBB complaints01
ALTO PHARMACY
Alto pharmacy Shipping SLA % (≤3 days)90.3%71.3%75%
Meds Shipped % (≤5 days)53.7%97.1%95%
Meds Delivered % (≤7 days)N/A87.2%90%
By medication (SLA)75%
Wegovy Oral (small n)90.0%N/A75%
Wegovy Injectable (small n)100.0%N/A75%
Heroes
$5.00
COGS per contact
COGS spend ÷ contacts QTD
90.5%
Phone SLA
Target 80–85%
90.2%
Chat SLA
Target 80–85%
43.4%
Email SLA
Target 80–85%
15.5%
Cohort refund
Target ≤15%
20.5%
Cohort voided
Target ≤16%
4.46
Blended reputation
4.5–4.6 range
Initiative updates
Account Management Tool Entering UAT
New customer account management tool entering UAT with Intouch once the Sales Tool rollout is complete. Successful UAT leads to a full team rollout replacing Retool for all FH+ customer support.
Rae Sykes · Jul 7
Metrics
Queue / SourceMetricQ3 QTDQ2Target
VOLUME
Total contacts QTD7,776165,288
↳ Cancel-reason tickets QTD3257,010
Voice AI self-service rate11.8%12.2%12–16%
BBB complaints QTD016
CCR QUEUE
CCRPhone SLA90.5%89.8%80–85%
CCRChat SLA90.2%92.9%80–85%
CCREmail SLA43.4%75.9%80–85%
CCRPhone AHT8.3 min8.8 min≤10 min
CCRChat AHT13.1 min39.5 min≤30 min
CRA QUEUE
CRAPhone SLA92.1%95.1%80–85%
CRAChat SLA89.8%87.2%80–85%
CRAEmail SLA100.0%98.3%80–85%
CRAPhone AHT8.2 min9.6 min≤10 min
CRAChat AHTN/A36.4 min≤30 min
REPUTATION
Blended (TP + FH+ App) (192 reviews)4.464.374.5–4.6
Trustpilot (51 reviews)4.244.41
FH+ Apple App Store (129 reviews)4.624.13
FH+ Google Play Store (12 reviews)3.674.00
Legacy Apple (deprecated) (56 reviews)4.274.54
Legacy Google (deprecated) (6 reviews)2.333.43